CJC-1295
CJC-1295 is a synthetic peptide analog of growth hormone–releasing hormone (GHRH) studied in controlled laboratory settings for its potential influence on growth hormone secretion pathways, peptide–receptor binding dynamics, and extended half-life modifications through DAC (Drug Affinity Complex) attachment.
For laboratory research use only. Not for human or veterinary use. Not intended for diagnostic, therapeutic, or clinical applications.
Purchase Options
CJC-1295 (Without DAC)
Form: Lyophilized Research Peptide • Purity: ≥98% • CAS: 87616-84-0
CJC-1295 without DAC (Modified GRF 1-29) lacks the albumin-binding DAC moiety, providing a shorter half-life useful for pulse-style studies. For scientific, non-human, in-vitro research only.
CJC-1295 (With DAC)
Form: Lyophilized Research Peptide • Purity: ≥98% • CAS: 863288-34-0
CJC-1295 with DAC includes a Drug Affinity Complex that prolongs exposure via albumin binding—useful where sustained signaling is desired. For scientific, non-human, in-vitro research only.
Shipping & Delivery
- 📦 UPS Ground(US): $15.00 — 5 business days
- 🚚 UPS 3 Day Select®(US): $20.00
- 🚚 UPS 2nd Day Air®(US): $25.00— 3 business days<
- 🆓 Free Shipping (US): Orders $200.00+ ship free
- 🌍 International Tracked: ( $45.00–$24.95 based on region
- 🎁 Free International Shipping: Orders $300+ qualify
CJC-1295 – With vs. Without DAC
CJC-1295 Without DAC
PubChem CID: 91976842
Molecular Formula: C152H252N44O42
Synonyms:
CJC1295 Without DAC
CJC1295 With DAC
L-Lysinamide, L-tyrosyl-D-alanyl-L-a-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-glutaminyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutaminyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-a-aspartyl-L-isoleucyl-L-leucyl-L-seryl-L-arginyl-N6-[3-(2,5-dihydro-2,5-dioxo-1H-
Molecular Weight: 3367.9 g/mol
Computed by PubChem: PubChem 2.1 (release 2021.05.07)
Date Created: 2015-11-05
Last Modified: 2025-07-28
CJC-1295 With DAC
PubChem CID: 91971820
Molecular Formula: C165H269N47O46
Synonyms:
CJC1295
62RC32V9N7
DTXSID501027567
DTXCID701513160
Molecular Weight: 3647.2 g/mol
Computed by PubChem: PubChem 2.1 (release 2021.05.07)
Date Created: 2015-11-02
Last Modified: 2025-07-28
CJC-1295 without DAC
CJC-1295 with DAC
Clinical Development & Research Focus
CJC-1295, available in both DAC (Drug Affinity Complex) and non-DAC forms, has been investigated in various preclinical and early-phase clinical research settings for its role in modulating growth hormone (GH) pathways and metabolic regulation.
- Growth Hormone Secretion Enhancement: Both forms of CJC-1295 have been studied for their ability to stimulate a physiologic release of GH. The DAC-conjugated form promotes prolonged GH elevation, while the non-DAC form induces a more immediate but shorter-lived response.
- Metabolic Effects: Research has explored their potential in influencing lean muscle mass, fat metabolism, and energy balance, with DAC formulations generally exhibiting extended systemic activity profiles.
- Tissue Regeneration & Repair: Investigations suggest involvement in cellular repair processes and tissue recovery mechanisms, driven by sustained GH and IGF-1 elevation, particularly with the DAC form.
- Pharmacokinetic Profiles: CJC-1295 with DAC demonstrates a significantly longer half-life due to its covalent binding to serum albumin, allowing for less frequent administration. The non-DAC version, lacking this modification, is rapidly cleared and requires more frequent dosing in experimental models.
It is important to emphasize that both variants of CJC-1295 are considered research chemicals intended solely for laboratory-based investigation. Neither form has received regulatory approval for therapeutic use in humans or animals.
Clinical Trial Findings & Efficacy
Early clinical trials and preclinical investigations have examined the pharmacokinetics, pharmacodynamics, and safety of both CJC-1295 with DAC and CJC-1295 without DAC in healthy adults and experimental models of growth hormone deficiency. Key findings include:
- Extended Half-Life (with DAC): The DAC-conjugated form exhibited a significantly prolonged half-life, remaining active in circulation for several days. This enables less frequent dosing and sustained GH stimulation over time.
- Rapid Clearance (without DAC): The non-DAC variant demonstrated a much shorter half-life, requiring more frequent administration to achieve comparable GH release, and is often used when pulse-like or acute GH stimulation is desired in research.
- GH and IGF-1 Elevation: Both forms led to increased levels of growth hormone and IGF-1. The DAC form resulted in prolonged elevation, while the non-DAC form produced a shorter, more transient rise.
- Dose-Dependent Response: The observed hormonal effects in both variants were dependent on dose and subject physiology, though the DAC version showed a more stable and predictable pharmacodynamic profile.
- General Safety Profile: Reported adverse effects across early studies were mild and included transient headaches and injection site reactions. Long-term safety has not been established for either form.
It is essential to emphasize that both forms of CJC-1295—with and without DAC—are classified strictly as investigational research compounds. They are not approved for any therapeutic or diagnostic use in humans or animals.
Key Scientific References
Further information on CJC-1295 with DAC and its research applications can be found in the following scientific literature:
- Sutton J, et al. Prolonged growth hormone-releasing activity of CJC-1295, a DAC:GRF analog, in healthy adults. J Clin Endocrinol Metab. 2006 Feb;91(2):479-88. PMID: 16405828
- Teichman SL, et al. Evaluation of growth hormone (GH) secretion patterns in normal subjects treated with CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2004 Dec;89(12):6021-30. PMID: 15579978
- Popovic V. Growth hormone-releasing peptides: CJC-1295, ipamorelin, and tesamorelin. Growth Horm IGF Res. 2012 Oct;22(5):211-5. PMID: 22900742
- Bredella MA, et al. Effects of CJC-1295, a long-acting growth hormone-releasing hormone analog, on muscle protein synthesis in healthy adults. J Clin Endocrinol Metab. 2006 Nov;91(11):4494-500. PMID: 17018933
Compliance Statement & Disclaimer
The products CJC-1295 with DAC and CJC-1295 without DAC are provided strictly for scientific research and laboratory development purposes only. These compounds are not classified as drugs, dietary supplements, or cosmetics, and they have not been evaluated by any regulatory authority for safety, efficacy, or suitability in humans or animals.
Any use of these materials outside of approved research settings—such as for diagnostic, therapeutic, or clinical applications—is expressly prohibited. By accessing, purchasing, or handling these substances, the user affirms compliance with all applicable local, state, national, and international laws and regulations regarding the handling of research chemicals.
Misuse or misrepresentation of these compounds for any non-research purpose is strictly forbidden.
Analytical Validation & Documentation (COA, HPLC, MS)
Each production lot is subjected to rigorous analytical validation to confirm quality, purity, and molecular identity under research-grade standards. Full supporting documentation is available upon request.
- COA (Certificate of Analysis): Includes batch number, purity percentage, traceability of each constituent ingredient, storage instructions, and full QC test results.
- HPLC (High-Performance Liquid Chromatography): Provides chromatographic confirmation of purity and compound homogeneity.
- MS (Mass Spectrometry): Confirms molecular weight and verifies structural integrity of the compound.
- Traceability: Documents are traceable to their respective manufacturing lot and are intended to support reproducibility and transparency in scientific investigation.
Displayed above: Sample Certificate of Analysis – AOD-9604 (3-page image preview)
Storage & Shipping
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures stability during transit and long-term storage. Below are the official recommendations:
- Stability During Shipping: Products are 100% stable for shipping for up to 3–4 months at ambient temperature.
- After Reconstitution: Once reconstituted with bacteriostatic water, the peptide must be stored in a refrigerator and will remain stable for up to 30 days.
- Room Temperature Storage: Lyophilized powder can be safely stored at room temperature until reconstitution, provided it remains sealed and protected from light.
- Refrigerated Storage (Short Term): Store under 4°C (39°F) if not used immediately. Suitable for storage up to several weeks or months.
- Frozen Storage (Long Term): For extended stability (months to years), store in a freezer at -80°C (-112°F).
Note: Avoid repeated freeze-thaw cycles. Always aliquot after reconstitution when necessary. Follow institutional safety protocols for handling all research compounds.
For advanced storage tips and reconstitution guidance, contact us or refer to our extended documentation.